LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

46.01 -2.52

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

45.81

Max

46.95

Galvenie mērījumi
By Trading Economics
Ienākumi	34M 22M
Pārdošana	16M 165M
P/E Sektora vidējais	48.435 77.256
Peļņas marža	13.598
Darbinieki	674
EBITDA	20M 38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+28.23% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1B 3.1B
Iepriekšējā atvēršanas cena	48.53
Iepriekšējā slēgšanas cena	46.01

Ziņu noskaņojums

By Acuity

29%

71%

86 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

31.35 / 32.36 Atbalsts un pretestība

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. nov. 21:06 UTC

Galvenie tirgus virzītāji

JBS Down After Trump Calls for Probe into Meat-Packing Companies

2025. g. 7. nov. 22:36 UTC

Peļņas

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

2025. g. 7. nov. 22:22 UTC

Peļņas

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

2025. g. 7. nov. 22:03 UTC

Peļņas

Constellation Software 3Q Rev $2.95B >CSU.T

2025. g. 7. nov. 22:03 UTC

Peļņas

Constellation Software 3Q Net $210M >CSU.T

2025. g. 7. nov. 22:03 UTC

Peļņas

Constellation Software 3Q EPS $9.89 >CSU.T

2025. g. 7. nov. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 7. nov. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 7. nov. 20:59 UTC

Peļņas

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

2025. g. 7. nov. 20:26 UTC

Tirgus saruna

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

2025. g. 7. nov. 20:22 UTC

Peļņas

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

2025. g. 7. nov. 20:04 UTC

Tirgus saruna

Oil Futures Close Choppy Week With Losses -- Market Talk

2025. g. 7. nov. 19:34 UTC

Tirgus saruna

Gold Posts Small Gain for Week -- Market Talk

2025. g. 7. nov. 19:31 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

2025. g. 7. nov. 19:17 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

2025. g. 7. nov. 19:09 UTC

Peļņas

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

2025. g. 7. nov. 19:08 UTC

Peļņas

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

2025. g. 7. nov. 18:31 UTC

Tirgus saruna

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

2025. g. 7. nov. 17:27 UTC

Tirgus saruna

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

2025. g. 7. nov. 17:20 UTC

Tirgus saruna

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

2025. g. 7. nov. 17:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 7. nov. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 7. nov. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 7. nov. 17:17 UTC

Iegādes, apvienošanās, pārņemšana

Satair Expects to Complete Purchase in Early 2026

2025. g. 7. nov. 17:17 UTC

Iegādes, apvienošanās, pārņemšana

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

2025. g. 7. nov. 17:15 UTC

Iegādes, apvienošanās, pārņemšana

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

2025. g. 7. nov. 17:09 UTC

Tirgus saruna

PENN Is Falling Further Behind Competitors -- Market Talk

2025. g. 7. nov. 16:49 UTC

Tirgus saruna

Losing ESPN Partnership Will Hurt PENN -- Market Talk

2025. g. 7. nov. 16:24 UTC

Tirgus saruna

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

2025. g. 7. nov. 16:17 UTC

Tirgus saruna

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

28.23% augšup

Prognoze 12 mēnešiem

Vidējais 60.6 USD 28.23%

Augstākais 65 USD

Zemākais 50 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

86 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.